Close menu


Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models

Mdegela, Mselenge (2022) BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in CCNE1-amplified ovarian cancer models. In: American Association for Cancer Research (AACR), 08-13th Apr 2022, New Orleans.

Item Type: Conference or Workshop Item (Poster)


A broad range of aggressive cancers harbor cyclin E1 (CCNE1) gene amplifications. CCNE1 amplification has been associated with poor survival in ovarian cancer, representing an unmet medical need. Cyclin E1 is the canonical binding partner of cyclin-dependent kinase 2 (CDK2) and the cyclin E1-CDK2 complex drives G1/S progression of the cell cycle. CDKs are a class of enzymes that, along with their regulatory cyclin binding partners, drive cell cycle progression. Cell lines harboring CCNE1 amplification are sensitive to CDK2 knockout or catalytic inhibition with ATP-competitive molecules, suggesting CDK2 may be an attractive therapeutic target for CCNE1-amplified cancers. Selectively inhibiting CDK2 for CCNE1-amplified tumors may limit off-target CDK-driven toxicities. BLU-222 is an orally available, selective investigational CDK2 inhibitor. The poster presents preclinical validation studies leading to the development of BLU-222 for the treatment of patients with ovarian cancer harboring a CCNE1 amplification. CCNE1 copy number increase was a strong predictor of response to CDK2 inhibition across tumor types in cellular systems. BLU-222 is a selective and potent CDK2 inhibitor that arrested cells at the G1/S boundary in an Rb-dependent manner. BLU-222 as monotherapy showed antitumor activity in a CCNE1-amplified CDX tumor model. The combinations of BLU-222 with carboplatin (SOC first-line treatment), BLU-222 with olaparib, and BLU-222 with gemcitabine all induced tumor regression that was sustained even after treatment cessation. Taken together, this evidence provides scientific rationale for the clinical development of BLU-222 as a monotherapy and in combination with SOC agents in CCNE1-amplified cancers.

PDF (Blueprint-Medicines-AACR-2022-BLU-222-Ovarian-Cancer-Preclinical-Poster)
Blueprint-Medicines-AACR-2022-BLU-222-Ovarian-Cancer-Preclinical-Poster.pdf - Published Version

Download (4MB) | Preview

More Information

Related URLs:
Depositing User: Mselenge Mdegela


Item ID: 17241
Official URL:

Users with ORCIDS

ORCID for Mselenge Mdegela: ORCID iD

Catalogue record

Date Deposited: 24 Jan 2024 09:49
Last Modified: 24 Jan 2024 10:00


Author: Mselenge Mdegela ORCID iD
Author: Mselenge Mdegela

University Divisions

Faculty of Health Sciences and Wellbeing > School of Psychology


Sciences > Biomedical Sciences

Actions (login required)

View Item (Repository Staff Only) View Item (Repository Staff Only)